

SWIXX AND NORGINE SIGN DEAL ON PLENVU FOR CEE

SWIXX ANNOUNCEMENT NO. 27

February 13th, 2020

Baar, Switzerland – Swixx BioPharma AG announced today the signing of a License and Distribution Agreement with Norgine B.V. of the Netherlands. The contract gives Swixx the right to commercialize Norgine’s next generation bowel cleanser, PLENVU[®], across Central and Eastern Europe, including Bosnia and Herzegovina, Bulgaria, Croatia, Czech Republic, Hungary, Kosovo, Montenegro, North Macedonia, Poland, Romania, Serbia, Slovakia, and Slovenia. PLENVU[®] (NER1006) is the first 1-litre polyethylene glycol (PEG) based bowel preparation to show superior, high-quality segmental cleansing of the colon compared to the current standard of care.[1] PLENVU[®] is registered throughout the European Union, and regulatory filings are in preparation for Bosnia, Kosovo, Montenegro, Northern Macedonia and Serbia.

“This PLENVU[®] deal marks a welcome deepening of our relationship with Norgine,” commented Swixx CEO, Jean-Michel Lespinasse, “We already market Norgine’s MOVIPREP[®] bowel cleanser in Bosnia and we are launching MOVIPREP[®] for Norgine in Serbia this year,” noted Lespinasse. “Adding PLENVU[®] to our gastrointestinal (GI) portfolio represents a great opportunity for Swixx, building on our existing excellent cooperation with Norgine. PLENVU[®], has the potential to help improve colonoscopy outcomes, patient experience and adherence.”

Swixx’s Medical Director, Dr. Laur Saar observed, “High quality cleansing is associated with higher lesion detection rates, bringing significant benefit to patients ” and added, “PLENVU[®] may be more comfortable for patients. By reducing the amount of bowel preparation volume to 1 litre, PLENVU[®] may improve patient experience and adherence to bowel cleansing instructions. Improved adherence to bowel preparation is known to reduce the need for repeat colonoscopy procedures, thereby reducing healthcare costs.”

About PLENVU[®]

PLENVU[®], Powder for Oral Solution (PEG 3350, Sodium Ascorbate, Sodium Sulfate, Ascorbic Acid, Sodium Chloride, and Potassium Chloride), is indicated in adults for bowel cleansing prior to any procedure requiring a clean bowel. .[2]

About Swixx BioPharma AG

Swixx now operates fully-owned subsidiaries across Central and Eastern Europe, offering coverage from Moscow to Prague and from Tallinn to Sofia. Net sales in 2019 were 143 million Euros and in 2020 should reach 225 million Euros. Established in 2014, Swixx has gathered outstanding specialty pharmaceutical, rare disease, medical device and OTC / consumer healthcare talent under one roof. The company specializes in representing research-based pharmaceutical, biotech, orphan, medical equipment and self-care brands. For more info about Swixx, please visit: www.swixxbiopharma.com

About Norgine

Norgine is a leading European specialist pharmaceutical company that has been bringing transformative medicines to patients for over a century. Our commitment to transforming people's lives drives everything we do and our European experience, fully integrated infrastructure and exceptional partnership approach enables us to quickly apply creative solutions to bring life-changing medicines to patients that they may not otherwise be able to access. Norgine is proud to have helped 22 million patients around the world in 2019 and generated €419 million in net product sales, a growth of 6% over 2018.

Norgine has a direct presence in 14 European countries, as well as Australia and New Zealand. We also have a strong global network of partnerships in non-Norgine markets. We are a flexible and fully integrated pharmaceutical business, with manufacturing (Hengoed, Wales and Dreux, France), third party supply networks and significant product development capabilities, in addition to our sales and marketing infrastructure. This enables us to acquire, develop and commercialise specialist and innovative products that make a real difference to the lives of patients around the world. Please visit www.norgine.com

In 2012, Norgine established Norgine Ventures, a complementary business which supports innovative healthcare companies through the provision of debt-like financing in Europe and the US. For more information, please visit www.norgineventures.com

NORGINE and the sail logo are trademarks of the Norgine group of companies.

Endnote:

- 1] Repici A., Amlani B., Uebel P., Schreiber S. Superior high-quality colon cleansing with 1L NER1006 versus sodium picosulfate + magnesium citrate, 2L polyethylene glycol + ascorbate, or oral sulfate solution: Post hoc pooled analysis of three randomised phase 3 clinical trials. #P0159. Monday 22 October. 12:30 – 13:30 CET. UEGW 2018
- 2] PLENVU® SmPC: <https://www.medicines.org.uk/emc/product/8578/smpc> Last accessed, February 2020

Contact:

Maja Boskovic, Public Affairs Officer, Swixx BioPharma A.G.

Maja.Boskovic@swixxbiopharma.com Tel: +381 11 4426 321

Note on Unsubscribing from Swixx Announcement Mailing List

In accordance with the GDPR (General Data Protection Regulation) provisos of the EU, should you wish to unsubscribe / opt out of our mailing list, please send to Maja.Boskovic@swixxbiopharma.com a one-line message „Please unsubscribe me.“ Thank you.